EE353 Incorporation of Cladribine for Patients With Multiple Sclerosis in a Health Insurance Company in Brazil: Cost-Effectiveness

To assess the cost-effectiveness ratio of Cladribine compared to Natalizumab and Ocrelizumab for patients aged 18 years or older with Highly Active Multiple Sclerosis (HAMS).

Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: J.M. Alves Junior, F.E. Prota, J.C.B. Martinelli, A. Chrispim, M. Serpeloni, I. Barreto, F.F. Christoforo, B.M. Nascimento, M. Ferreira Source Type: research